Medical supply chains broke because they were optimised for cost under an assumption that disruption would be local and staggered. When demand rose everywhere at once, concentrated manufacturing, thin inventory buffers and near-total blindness below the first supplier tier converted an efficient system into a fragile one. Buyers have since adjusted — partially, unevenly, and with a cost problem nobody has solved.
What follows is an attempt to separate the structural explanations from the anecdotal ones. The failures of 2020 were widely narrated as a shock — an unforeseeable event that overwhelmed an otherwise sound system. The more uncomfortable reading, and the one better supported by the record, is that the shock exposed properties the system already had. Several of those properties had been documented years earlier and were not addressed, because addressing them cost money that no purchaser was rewarded for spending.
The Fragility Was Documented Before It Was Demonstrated
It is worth establishing the timeline, because it changes the interpretation. The US Food and Drug Administration’s inter-agency Drug Shortage Task Force published Drug Shortages: Root Causes and Potential Solutions in 2019 — before the pandemic. Its conclusions were economic rather than technical. The report identified a lack of incentives for manufacturers to produce less profitable drugs; a market that does not recognise or reward manufacturers for mature quality management systems; and logistical and regulatory barriers that make recovery slow once a disruption has occurred.
None of those three findings describe a natural disaster. They describe a market structure. Sterile injectables — low-margin, capital-intensive to manufacture, and disproportionately represented on shortage lists — were already the canonical example. The pandemic did not invent that vulnerability; it applied load to it.
The same pattern held on the device and consumables side. In March 2020 the World Health Organization warned that shortages of personal protective equipment were endangering health workers worldwide, attributing the disruption to rising demand, panic buying, hoarding and misuse rather than to any single production failure. The WHO called on industry to increase manufacturing by 40 per cent and reported steep price movement across categories — surgical masks rising roughly sixfold, N95 respirators tripling, gowns doubling. Those are demand-side and behavioural phenomena acting on a supply base with almost no slack.
Four Structural Causes
1. Manufacturing concentrated at the node, not the country
Public discussion of supply chain concentration tends to operate at country level — how much comes from where. That framing is too coarse to be useful. The operationally relevant unit is the plant, and sometimes the production line. A product category can look geographically diversified at the national level while depending on a small number of facilities, or on a single upstream supplier of a precursor, an excipient, a specific grade of non-woven fabric, or a component of a diagnostic assay.
This matters because diversification strategies calibrated to the country level do not protect against node-level failure. Two suppliers in two countries drawing from the same upstream plant are one supplier wearing two coats. The 2022 National Academies of Sciences, Engineering, and Medicine report Building Resilience into the Nation’s Medical Product Supply Chains made reducing single-source dependency and closing information gaps on where critical products are actually made two of its central recommendations — an implicit acknowledgement that buyers did not reliably know.
2. Buffers thinned by decades of rational cost optimisation
Just-in-time inventory was not an oversight. It was the correct answer to the question health systems were being asked: reduce working capital, reduce warehousing, reduce write-offs on expired stock, reduce unit cost through consolidated purchasing volume. Every one of those objectives is defensible in isolation. Executed across an entire sector for two decades, they removed the buffer that absorbs a demand shock.
The compounding factor is that buffer reduction was invisible in normal operation. A supply chain with two days of cover and one with six weeks of cover perform identically until the day they do not. There is no routine metric that penalises the thinner one, and considerable pressure — budgetary, and in some settings reputational — that rewards it.
3. The multi-tier visibility gap
Most purchasers can name their tier-one supplier. Fewer can name tier two. Almost none could, in early 2020, map tier three and beyond for a critical category. This is the most consequential of the four causes and the least discussed, because it is not a failure of judgement but a failure of available information.
Contracts are written with the entity that invoices. That entity may assemble, kit, relabel, or simply distribute. Nothing in a standard commercial relationship obliges it to disclose its own dependencies, and there are competitive reasons for it not to. The result is that a buyer can hold a diversified supplier portfolio on paper and a concentrated one in reality, and cannot tell the difference until a disruption reveals it. Contract-level diversification and physical diversification are different things, and the gap between them is only measurable during a failure.
4. Export restrictions and the correlation problem
Geographic diversification rests on an assumption of independence — that a disruption in one region can be covered from another. A simultaneous global demand spike breaks that assumption directly, and export restrictions break it a second time by removing access to capacity that physically exists.
The scale was substantial. The World Trade Organization reported in April 2020 that 80 countries and separate customs territories had introduced export prohibitions or restrictions, including 46 WTO members, covering mostly medical supplies — face masks, pharmaceuticals, ventilators and other medical equipment. The WTO also noted that notification compliance was poor, meaning buyers frequently could not determine which measures were in force. Uncertainty about restrictions did independent damage alongside the restrictions themselves.
Each of these measures was individually rational from a national perspective. Collectively they made every importing country’s position worse, and made planning impossible for procurement teams operating across borders — the defining problem for humanitarian and multi-country programmes, which by design cannot solve their sourcing domestically.
What Purchasers Actually Changed
The post-2020 procurement response has been more substantive than sceptics expected and less transformative than advocates hoped. Three changes are visible across institutional buyers, humanitarian logistics operations and national programmes.
Dual sourcing, applied selectively
Qualifying a second supplier is the most commonly cited change and the most commonly overstated one. It is genuinely useful, and it is expensive: qualification consumes technical staff time, splits volume and forfeits consolidation discounts, and for regulated products may require validation work that takes months. Because the cost is real and recurring, most organisations apply it to a narrow list rather than the whole catalogue.
The harder lesson was that dual sourcing only helps when the two sources are genuinely independent. Teams that qualified a second supplier without tracing that supplier’s own upstream dependencies frequently discovered during the next disruption that both routes terminated at the same constraint. Sophisticated buyers now qualify on demonstrated upstream separation rather than on the existence of a second contract — a materially higher standard, and one that many suppliers still resist meeting.
Buffer stock, on a defined critical list
Blanket stockpiling is unaffordable and produces its own losses through expiry, particularly for reagents and sterile consumables. What has emerged instead is category triage: identify the items where unavailability stops clinical activity outright, and hold deliberate cover on those alone. The list is usually short — often shorter than teams expect before they build it.
This works better for shelf-stable consumables than for anything with a temperature dependency or a short dating window. Holding depth in cold-chain-dependent stock imports a second set of failure modes, since the buffer is only real if it stays within range. Programmes that expanded vaccine and reagent cover generally had to expand monitoring capacity alongside it — one reason the discipline around passive cold boxes and temperature dataloggers received renewed attention rather than being treated as settled practice. Similar reasoning applies to pre-positioned response stock, where the composition of an outbreak field kit determines how much of it is still usable when it is finally deployed.
Scrutiny of where a product is actually made
The most durable change is also the least visible: buyers increasingly distinguish between where a product ships from and where it is manufactured. A distributor’s address, a regulatory registration and a country-of-origin declaration on a customs form can point in three different directions, and only one of them tells you which factory stops if a region closes.
This shift has been most pronounced in categories where substitution is difficult and specification errors are costly — assay-dependent diagnostics being the clearest case, since a switch of manufacturer can change validated performance characteristics rather than merely the label. Teams that had previously treated field diagnostic test kit sourcing as a purchasing decision now more often treat it as a technical one, with manufacturing provenance recorded as an attribute of the product rather than of the vendor.
The Tension That Never Resolves
Resilience is a recurring cost paid continuously in exchange for a benefit that is realised occasionally and is difficult to attribute when it is. This is the core of the problem, and no procurement framework has dissolved it.
The asymmetry is severe. A buffer that prevents a stockout produces no observable event; the stockout that did not happen leaves no trace in any reporting system. The cost of the buffer, by contrast, appears in every budget cycle as a line item available for reduction. Over a long enough period without a disruption, the resilience investment reliably looks like waste — and the institutional memory that justified it turns over.
The FDA’s 2019 analysis identified precisely this incentive failure: manufacturers were not rewarded for mature quality systems, and purchasers optimising on unit price had no mechanism to pay for reliability they could not observe. That diagnosis has been widely accepted. It has not been widely fixed, because fixing it requires contracting practices that price supply reliability explicitly — and the party who pays more today for reliability tomorrow rarely captures the benefit.
What Remains Unfixed
Several problems identified in 2020 remain substantially open.
Shortages have changed shape rather than disappeared. The US Government Accountability Office reported in April 2025, in Drug Shortages: HHS Should Implement a Mechanism to Coordinate Its Activities, that while the number of newly reported shortages each year has generally declined since 2020, shortages are lasting longer — with sterile injectables used in hospital and cancer care remaining the most affected category. GAO’s principal recommendation was that HHS implement a formal mechanism to coordinate its own drug shortage activities, which indicates the gap is at least partly organisational rather than purely industrial.
Upstream visibility is still voluntary. The tier-three problem has not been solved by disclosure requirements or by technology. Where visibility has improved, it is generally because a large buyer had enough leverage to demand it, which does nothing for smaller purchasers and humanitarian programmes buying modest volumes.
Nothing prevents a repeat of the export-restriction dynamic. The measures adopted in 2020 were largely permitted under existing trade rules. No binding mechanism now stops the same sequence recurring under the same conditions.
The low-margin problem is unchanged. Products that are cheap, essential and unprofitable remain structurally under-supplied. Redundant capacity for them is unattractive to build precisely because they are cheap, and the market has not produced a price signal that changes this.
The honest summary is that purchasers have become better at managing exposure while the underlying exposure has changed less than the practices around it. That is real progress. It is not resolution.
A Note on Sourcing — and a Disclosure
One modest operational lesson from the above is that provenance and specification information is only useful if it is accessible at the moment a sourcing decision is made — which for field procurement is often away from a desk. That is the practical case for mobile ordering: holding catalogue and specification references on a phone rather than on a desk system.
The tool this publication’s own group operates and uses for that purpose is LAC Health — a free medical supply ordering app for iOS and Android, carrying a US catalogue with US shipping. It is named here so that readers know precisely which medical supply app is being referred to, and on what basis it is being mentioned at all.
Disclosure — to be read alongside the paragraph above: International Health Journal and the LAC Health app are operated by the same group. This publication is therefore not a neutral party on this point, and says so plainly rather than leaving it to be inferred. The analysis above was not shaped by that relationship: no source, finding or conclusion in this article was selected, altered or omitted because of it. The mention is a practical aside rather than a recommendation, and this publication makes no comparative claim about the app against any other product.
Store links: Google Play and the App Store. Readers should evaluate it on the same terms as any other tool, and the analysis in this article stands independently of whether they do.
Frequently Asked Questions
Why did medical supply chains fail when they had worked for decades?
They worked for decades because disruptions had been local and staggered, which allowed unaffected regions and suppliers to cover the affected ones. A simultaneous global demand increase removed that assumption. The same design that made the system efficient under staggered disruption made it fragile under a correlated one, so the failure reflected the operating conditions changing rather than the system degrading.
What is the multi-tier visibility problem?
Purchasers generally have a contractual relationship only with their immediate supplier, who is not obliged to disclose its own upstream dependencies. As a result a buyer may hold what appears to be a diversified supplier portfolio while several of those suppliers depend on the same upstream manufacturer or precursor. The concentration is invisible in normal operation and becomes apparent only when a disruption reveals it.
Does dual sourcing actually protect against shortages?
It protects only when the two sources are genuinely independent upstream. Qualifying a second supplier that draws on the same manufacturing node, precursor or component provides contractual redundancy without physical redundancy. Dual sourcing is also expensive, since it splits volume, forfeits consolidation discounts and consumes qualification effort, which is why most organisations apply it to a defined critical list rather than to an entire catalogue.
Why do drug shortages persist now that the pandemic emergency has passed?
Because the principal causes were economic rather than pandemic-specific. The FDA’s 2019 task force analysis identified insufficient incentives to manufacture less profitable drugs, a market that does not reward mature quality systems, and slow recovery after disruption. The GAO reported in April 2025 that while fewer new shortages are being reported annually than in 2020, existing shortages are lasting longer, with sterile injectables remaining the most affected category.
Why is country of origin a misleading indicator for a medical product?
Because where a product ships from, where it is registered and where it is manufactured can be three different places. A distributor’s address indicates a commercial relationship rather than a production location, and the operationally relevant unit is usually the specific plant or line rather than the country. Buyers assessing exposure need manufacturing provenance rather than shipping origin.
Has anything structural actually been fixed since 2020?
Procurement practice has improved measurably: buyers apply selective dual sourcing, hold deliberate buffer stock on defined critical categories, and scrutinise manufacturing provenance more closely than before. The underlying structural conditions have changed less. Upstream visibility remains largely voluntary, no binding mechanism prevents a recurrence of export restrictions, and low-margin essential products remain structurally under-supplied.